Movement disorders : official journal of the Movement Disorder Society · 2025
Plasma Markers of Astrocytic and Axonal Integrity in Idiopathic/Isolated REM Sleep Behavior Disorder (iRBD) as Predictors of Dementia with Lewy Bodies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Delva Aline, Zatti Cinzia, Pelletier Amélie, Montplaisir Jacques, Gagnon Jean-François, Kollmorgen Gwendlyn, Kam-Thong Tony, Kustermann Thomas, Machado Venissa, Postuma Ronald B
Аннотация
BACKGROUND: Plasma biomarkers of neurodegeneration, astrogliosis, and neuroinflammation have been studied as potential biomarkers in neurodegenerative diseases. This study investigated whether these markers may predict phenoconversion to Parkinson's disease or dementia with Lewy bodies (DLB) in idiopathic/isolated REM sleep behavior disorder (iRBD).
METHODS: In this longitudinal, single-center, iRBD cohort study (enrolled 2004-2022), plasma glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), neurofilament light chain (NfL), snare-associated protein 25 (SNAP25), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and chitinase 3-like protein (YKL-40) were measured using NeuroToolKit (Roche Diagnostics International Ltd). Associations between baseline plasma biomarkers and eventual development of manifest synucleinopathy during follow-up (up to 11 years) were assessed.
RESULTS: A total of 143 iRBD participants (110 male, 67.7 ± 8.0 years) were included. Compared with non-phenoconverters, DLB-converters had higher baseline GFAP (0.115 vs. 0.071 ng/ml, P = 0.002) and NfL (3.55 vs. 2.51 pg/ml, P = 0.010). Baseline levels predicted DLB using non-phenoconverters without mild cognitive impairment as reference with area under the curve (AUC) = 0.79 for GFAP and 0.84 for NfL.
CONCLUSION: Higher plasma GFAP and NfL were associated with increased risk of developing DLB in prodromal synucleinopathies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
METHODS: In this longitudinal, single-center, iRBD cohort study (enrolled 2004-2022), plasma glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), neurofilament light chain (NfL), snare-associated protein 25 (SNAP25), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and chitinase 3-like protein (YKL-40) were measured using NeuroToolKit (Roche Diagnostics International Ltd). Associations between baseline plasma biomarkers and eventual development of manifest synucleinopathy during follow-up (up to 11 years) were assessed.
RESULTS: A total of 143 iRBD participants (110 male, 67.7 ± 8.0 years) were included. Compared with non-phenoconverters, DLB-converters had higher baseline GFAP (0.115 vs. 0.071 ng/ml, P = 0.002) and NfL (3.55 vs. 2.51 pg/ml, P = 0.010). Baseline levels predicted DLB using non-phenoconverters without mild cognitive impairment as reference with area under the curve (AUC) = 0.79 for GFAP and 0.84 for NfL.
CONCLUSION: Higher plasma GFAP and NfL were associated with increased risk of developing DLB in prodromal synucleinopathies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.